{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T19:58:02Z","timestamp":1784059082143,"version":"3.55.0"},"reference-count":26,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100004735","name":"Hunan Provincial Natural Science Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004735","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2023,2]]},"DOI":"10.1016\/j.ejmech.2022.115016","type":"journal-article","created":{"date-parts":[[2022,12,15]],"date-time":"2022-12-15T20:35:13Z","timestamp":1671136513000},"page":"115016","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Design, synthesis and biological evaluation of novel quinazolinone derivatives as CRBN E3 ligase modulators"],"prefix":"10.1016","volume":"247","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7646-8537","authenticated-orcid":false,"given":"Linyi","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renhong","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haixia","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chaowei","family":"Ren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuedong","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xing","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Kong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Biao","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5266-7673","authenticated-orcid":false,"given":"Xiaobao","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.ejmech.2022.115016_bib1","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1007\/s11899-019-00536-6","article-title":"IMiDs new and old","volume":"14","author":"Yamshon","year":"2019","journal-title":"Curr. Hematol. Malig. R"},{"issue":"20","key":"10.1016\/j.ejmech.2022.115016_bib2","doi-asserted-by":"crossref","first-page":"2101","DOI":"10.1200\/JCO.2018.77.9637","article-title":"Next-generation drugs targeting the cereblon ubiquitin ligase","volume":"36","author":"Holstein","year":"2018","journal-title":"J. Clin. Oncol."},{"issue":"5971","key":"10.1016\/j.ejmech.2022.115016_bib3","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1126\/science.1177319","article-title":"Identification of a primary target of thalidomide teratogenicity","volume":"327","author":"Ito","year":"2010","journal-title":"Science"},{"issue":"4","key":"10.1016\/j.ejmech.2022.115016_bib4","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1182\/blood-2014-02-557819","article-title":"Identification of cereblon-binding proteins and relationship with response and survival after IMiDs in multiple myeloma","volume":"124","author":"Zhu","year":"2014","journal-title":"Blood"},{"issue":"6168","key":"10.1016\/j.ejmech.2022.115016_bib5","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1126\/science.1244851","article-title":"Lenalidomide causes selective degradation of IKZF1 and IKZF3 in multiple myeloma cells","volume":"343","author":"Kronke","year":"2014","journal-title":"Science"},{"issue":"6168","key":"10.1016\/j.ejmech.2022.115016_bib6","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1126\/science.1244917","article-title":"The myeloma drug lenalidomide promotes the cereblon-dependent destruction of Ikaros proteins","volume":"343","author":"Lu","year":"2014","journal-title":"Science"},{"issue":"21","key":"10.1016\/j.ejmech.2022.115016_bib7","doi-asserted-by":"crossref","first-page":"2963","DOI":"10.1182\/blood.V120.21.2963.2963","article-title":"CC-122 is a novel pleiotropic pathway modifier with potent in vitro immunomodulatory and anti-angiogenic properties and in vivo anti-tumor activity in hematological cancers","volume":"120","author":"Gandhi","year":"2012","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.ejmech.2022.115016_bib8","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1021\/acs.jmedchem.6b01921","article-title":"A cereblon modulator (CC-220) with improved degradation of ikaros and aiolos","volume":"61","author":"Matyskiela","year":"2018","journal-title":"J. Med. Chem."},{"issue":"7611","key":"10.1016\/j.ejmech.2022.115016_bib9","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/nature18611","article-title":"A novel cereblon modulator recruits GSPT1 to the CRL4(CRBN) ubiquitin ligase","volume":"535","author":"Matyskiela","year":"2016","journal-title":"Nature"},{"issue":"4","key":"10.1016\/j.ejmech.2022.115016_bib10","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1021\/acs.jmedchem.0c01489","article-title":"CC-90009: a cereblon E3 ligase modulating drug that promotes selective degradation of GSPT1 for the treatment of acute myeloid leukemia","volume":"64","author":"Hansen","year":"2021","journal-title":"J. Med. Chem."},{"issue":"13","key":"10.1016\/j.ejmech.2022.115016_bib11","doi-asserted-by":"crossref","first-page":"6648","DOI":"10.1021\/acs.jmedchem.9b01928","article-title":"Discovery of CRBN E3 ligase modulator CC-92480 for the treatment of relapsed and refractory multiple myeloma","volume":"63","author":"Hansen","year":"2020","journal-title":"J. Med. Chem."},{"issue":"13","key":"10.1016\/j.ejmech.2022.115016_bib12","doi-asserted-by":"crossref","first-page":"5498","DOI":"10.1039\/D2CS00197G","article-title":"Chasing molecular glue degraders: screening approaches","volume":"51","author":"Domostegui","year":"2022","journal-title":"Chem. Soc. Rev."},{"key":"10.1016\/j.ejmech.2022.115016_bib13","doi-asserted-by":"crossref","DOI":"10.3389\/fchem.2022.934337","article-title":"Key considerations in targeted protein degradation drug discovery and development","volume":"10","author":"Qin","year":"2022","journal-title":"Front. Chem."},{"key":"10.1016\/j.ejmech.2022.115016_bib14","volume":"vol. 39","author":"Michot","year":"2021"},{"issue":"7512","key":"10.1016\/j.ejmech.2022.115016_bib15","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1038\/nature13527","article-title":"Structure of the DDB1-CRBN E3 ubiquitin ligase in complex with thalidomide","volume":"512","author":"Fischer","year":"2014","journal-title":"Nature"},{"issue":"9","key":"10.1016\/j.ejmech.2022.115016_bib16","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1038\/nsmb.2874","article-title":"Structure of the human Cereblon-DDB1-lenalidomide complex reveals basis for responsiveness to thalidomide analogs","volume":"21","author":"Chamberlain","year":"2014","journal-title":"Nat. Struct. Mol. Biol."},{"issue":"7559","key":"10.1016\/j.ejmech.2022.115016_bib17","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1038\/nature14610","article-title":"Lenalidomide induces ubiquitination and degradation of CK1a in del(5q) MDS","volume":"523","author":"Kronke","year":"2015","journal-title":"Nature"},{"issue":"2","key":"10.1016\/j.ejmech.2022.115016_bib18","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1182\/blood.2019000789","article-title":"Patterns of substrate affinity, competition, and degradation kinetics underlie biological activity of thalidomide analogs","volume":"134","author":"Sperling","year":"2019","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.ejmech.2022.115016_bib19","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1182\/blood-2015-02-628669","article-title":"CC-122, a pleiotropic pathway modifier, mimics an interferon response and has antitumor activity in DLBCL","volume":"126","author":"Hagner","year":"2015","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.ejmech.2022.115016_bib20","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1038\/s41375-019-0620-8","article-title":"Iberdomide (CC-220) is a potent cereblon E3 ligase modulator with antitumor and immunostimulatory activities in lenalidomide- and pomalidomide-resistant multiple myeloma cells with dysregulated CRBN","volume":"34","author":"Bjorklund","year":"2020","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/j.ejmech.2022.115016_bib21","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1097\/PPO.0000000000000354","article-title":"Mechanism of action and novel IMiD-based compounds and combinations in multiple myeloma","volume":"25","author":"Nooka","year":"2019","journal-title":"Cancer J."},{"issue":"7","key":"10.1016\/j.ejmech.2022.115016_bib22","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1021\/acs.biochem.8b01307","article-title":"Evolving rules for protein degradation? Insights from the zinc finger degrome","volume":"58","author":"Buhimschi","year":"2019","journal-title":"Biochemistry"},{"key":"10.1016\/j.ejmech.2022.115016_bib23","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.38430","article-title":"Thalidomide promotes degradation of SALL4, a transcription factor implicated in Duane Radial Ray syndrome","volume":"7","author":"Donovan","year":"2018","journal-title":"Elife"},{"issue":"10","key":"10.1016\/j.ejmech.2022.115016_bib24","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1038\/s41589-018-0129-x","article-title":"SALL4 mediates teratogenicity as a thalidomide-dependent cereblon substrate","volume":"14","author":"Matyskiela","year":"2018","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.ejmech.2022.115016_bib25","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.ejmech.2019.01.023","article-title":"A novel cereblon modulator for targeted protein degradation","volume":"166","author":"Kim","year":"2019","journal-title":"Eur. J. Med. Chem."},{"issue":"4","key":"10.1016\/j.ejmech.2022.115016_bib26","doi-asserted-by":"crossref","first-page":"683","DOI":"10.3109\/10428194.2012.728597","article-title":"Molecular mechanism of action of immune-modulatory drugs thalidomide, lenalidomide and pomalidomide in multiple myeloma","volume":"54","author":"Zhu","year":"2013","journal-title":"Leuk. Lymphoma"}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523422009187?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523422009187?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T14:49:38Z","timestamp":1759330178000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523422009187"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2]]},"references-count":26,"alternative-id":["S0223523422009187"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2022.115016","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2023,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Design, synthesis and biological evaluation of novel quinazolinone derivatives as CRBN E3 ligase modulators","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2022.115016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"115016"}}